Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody

Journal of Pediatrics

Volumn 143, Issue 1, 2003, Pages 123-126

  DeVincenzo, John P ^a,b   Aitken, Jody ^a   Harrison, Lisa ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; FEMALE; HOSPITALIZATION; HUMAN; INFANT; MALE; NEWBORN; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS LOAD;

EID: 0042243531     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(03)00213-0     Document Type: Article

References (11)

1. Graham BS, Davis TH, Tang YW, Gruber WC. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr Res 1993;34:167-72.
2. Prince GA, Hemming VG, Horswood RL, Channock RM. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Research 1985;3:193-206.
3. Siber GR, Leszczynski J, Pena-Cruz V, Ferren-Gardner C, Anderson R, Hemming VG, et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis 1992;165:456-63.
4. Connor E, Group TPS. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
5. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176:1215-24.
6. Malley R, DeVincenzo J, Ramil O, Dennehy P, Meissner H, Gruber W, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants using humanized monoclonal antibody to RSV F protein. J Infect Dis 1998;178:1555-61.
7. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
8. Buckingham S, Bush A, DeVincenzo J. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J 2000;19:113-7.
9. DeVincenzo J, Bush A, Harrison L, Buckingham S, Murphy J, Prinz A, et al. Influence of host and viral factors in respiratory syncytial virus (RSV) duration of hospitalization [abstract]. Pediatr Res 2001;237A:1352.
10. Siber GR, Leombruno D, Leszczynski J, McIver J, Bodkin D, Gonin R, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 1994;169:1368-73.
11. DeVincenzo JP, Montana JB, Krishna Murthy GG, Skornik WA, Brain JD, McIver J, et al. Aerosolized respiratory syncytial virus (RSV) antibody treatment of RSV-infected cotton rats [abstract]. Infectious Diseases Society of America, New Orleans, Louisiana; 1996. Vol. 34:101.